Data / Form D filings / Resolys Bio, Inc.
Resolys Bio, Inc.: Form D filings
Resolys Bio, Inc., a biotechnology company in Delanson, NY, filed 4 Form D notices with the SEC between 2016 and 2023. The latest, on June 21, 2023, reports $50,000 sold of a $5 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 545 WESTFALL ROAD, Delanson, NY, 12053
- Phone
- (518) 872-1144
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 504
- SEC identifier (CIK)
- 1674941
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 21, 2023 | New notice | $5,000,000 | $50,000 | $4,950,000 | 1 | Jun 7, 2023 | sec.gov |
| Sep 25, 2017 | Amendment | $6,000,000 | $200,000 | $5,800,000 | 1 | Sep 11, 2017 | sec.gov |
| Dec 5, 2016 | Amendment | $10,000,000 | $0 | $10,000,000 | 0 | Yet to occur | sec.gov |
| May 19, 2016 | New notice | $7,000,000 | $0 | $7,000,000 | 0 | Yet to occur | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Damian Marron | Director | |
| Thomas Hatch | Director | |
| McKay Belk | Director | |
| Richard Sandberg | Executive Officer | |
| John McMichael | Director | |
| Stephen Hill | Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Jun 19, 2023 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Resolys Bio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.